A Phase 2 Study of IPI-926 in Patients With Myelofibrosis.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Patidegib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Biomarker; Therapeutic Use
- Sponsors Infinity Pharmaceuticals
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jun 2012 New source identified and integrated (2011-0445: M.D. Anderson Cancer Center).
- 18 Jun 2012 Status changed from recruiting to discontinued, according to an Infinity Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History